This SDS packet was issued with item:

078393384

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078916161

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078393459



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Vers 4.1	ion	Revision Date: 10/31/2016		DS Number: 6543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016			
SEC	TION 1	. IDENTIFICATION						
	Produc	t name	:	Human Gonadotropin Chorionic / Serum Gonadotropin For mulation				
	Manufacturer or supplier's details							
	Compa	ny name of supplier	:	Merck & Co., Inc				
	Addres	S	:	2000 Galloping Hill Road Kenilworth - New Jersey - USA 1685				
	Teleph	one	:	908-740-4000				
	Telefax		:	908-735-1496				
	Emerge	ency telephone	:	1-908-423-6000				
	E-mail address		:	EHSDATASTEWARD@merck.com				
Recommended use of the c Recommended use		hen :	nical and restriction					
SEC	TION 2	. HAZARDS IDENTIFI	CA	TION				
	GHS cl	assification in accord	dan	ce with 29 CFR 19	10.1200			
	Reprod	luctive toxicity	:	Category 1A				
	system	c target organ ic toxicity - repeated re (Oral)	:	Category 1 (ovari	es)			
	GHS la	bel elements						
	Hazard	pictograms	:					
	Signal	Word	:	Danger				

 Hazard Statements
 : H360Fd May damage fertility. Suspected of damaging the unborn child.

 H372 Causes damage to organs (ovaries) through prolonged or repeated exposure if swallowed.

 Precautionary Statements
 : Prevention:

P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood.



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

sion	Revision Date: 10/31/2016	SDS Number: 636543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016
		P264 Wash sk P270 Do not ea	reathe mist or vapors. in thoroughly after handling. at, drink or smoke when using this product. otective gloves/ protective clothing/ eye protectio
		Response: P308 + P313 II attention.	F exposed or concerned: Get medical advice/
		Storage: P405 Store loc	ked up.
		Disposal:	
		-	of contents/ container to an approved waste dis-
Othe	r hazards		
None	known.		

Substance / Mixture	:	Mixture
---------------------	---	---------

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Gonadotropin, pregnant mare serum	9002-70-4	>= 0.1 - < 1
Gonadotropin, chorionic	9002-61-3	>= 0.1 - < 1

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
lf inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

2/14



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 4.1	Revision Date: 10/31/2016	SDS Number: 636543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016
	t important symptoms effects, both acute and yed	child.	e fertility. Suspected of damaging the unborn age to organs through prolonged or repeated wallowed.
Prote	ection of first-aiders	and use the	bonders should pay attention to self-protection, recommended personal protective equipment tential for exposure exists.
Note	s to physician	: Treat sympto	pmatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Ver	sion	Revision Date:	SDS Number:	Date of last issue: 08/09/2016
4.1		10/31/2016	636543-00005	Date of first issue: 05/03/2016
		ds and materials for iment and cleaning up	For large spills, containment to can be pumped container. Clean up remai absorbent. Local or nationa disposal of this employed in the determine whic Sections 13 and	ert absorbent material. provide diking or other appropriate keep material from spreading. If diked material , store recovered material in appropriate ning materials from spill with suitable al regulations may apply to releases and material, as well as those materials and items e cleanup of releases. You will need to h regulations are applicable. d 15 of this SDS provide information regarding national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe vapors or spray mist. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice. Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Gonadotropin, pregnant mare serum	9002-70-4	TWA	4 µg/m3 (OEB 4)	Merck
		Wipe limit	40 µg/100 cm²	Merck



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

sion	Revision Date: 10/31/2016		S Number: 6543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016		
Gona	dotropin, chorionic		9002-61-3	TWA	3 µg/m3	Merck
	1 /			Wipe limit	25 µg/100 cm ²	Merck
				TŴA	OEB 4	Merck
Engin	eering measures	:	Use with local Dust formatic product. In ac limitations of workplaces h assessment. Particulates N dust, 5 mg/m Particles (inse	I exhaust ventil on may be relev ddition to substa concentrations ave to be consi Relevant limits Not Otherwise F 3 - respirable fr oluble or poorly mg/m3 - respi	e concentrations. ation. ant in the processing ance-specific OELs, of particulates in the dered in workplace r include: OSHA PEL Regulated of 15 mg/r action; and ACGIH 1 soluble) Not Otherw rable particles, 10 m	general air at for n3 - total IWA for vise
Perso	onal protective equip	ment				
	ratory protection	:	maintain vapa concentration unknown, app Follow OSHA use NIOSH/M by air purifyin hazardous ch supplied resp release, expo	or exposures be as are above re- propriate respira respirator regu ASHA approved g respirators ag nemical is limite pirator if there is poure levels are where air purif	entilation is recomme elow recommended l commended limits or atory protection shou lations (29 CFR 191 I respirators. Protect gainst exposure to a d. Use a positive pre any potential for un unknown, or any oth ying respirators may	imits. Where r are uld be worn. 10.134) and ion provided ny essure air controlled ner
	protection aterial	:	Chemical-res	istant gloves		
Re	emarks	:	on the conce time is not de For special a resistance to gloves with th	ntration specific stermined for the pplications, we chemicals of th	nds against chemica to place of work. Br e product. Change g recommend clarifyin e aforementioned pr acturer. Wash hands rkday.	eakthrough loves often! g the rotective
Еуе р	rotection	:	Wear the follo Safety glasse		protective equipmer	nt:
Skin a	and body protection	:	resistance da potential. Skin contact	ta and an asse	e clothing based on c ssment of the local e d by using imperviou ots, etc).	exposure



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 4.1	Revision Date: 10/31/2016		S Number: 6543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016			
Ну	Hygiene measures		: Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.				
SECTIO	ON 9. PHYSICAL AND CHI	EMI		3			
Ар	pearance	:	liquid				
Co	lor	:	No data available	9			
Oc	lor	:	No information av	vailable.			
Oc	lor Threshold	:	No data available)			
рH	I	:	No data available)			
Me	elting point/freezing point	:	No data available)			
	tial boiling point and boiling nge	:	No data available				
Fla	ash point	:	No data available				
Ev	aporation rate	:	No data available				
Fla	ammability (solid, gas)	:	Not applicable				
Up	per explosion limit	:	No data available				
Lo	wer explosion limit	:	No data available				
Va	por pressure	:	No data available				
Re	lative vapor density	:	No data available				
De	ensity	:	No data available				
So	lubility(ies) Water solubility	:	No data available	•			
	rtition coefficient: n- tanol/water	:	No data available				
Au	toignition temperature	:	No data available	9			
De	composition temperature	:	No data available				
Vis	scosity Viscosity, dynamic Viscosity, kinematic	:	No data available No data available				
	viscosity, kinematic	•		2			



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 4.1	Revision Date: 10/31/2016		S Number: 6543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016
Exp	losive properties	:	Not explosive	
Oxi	dizing properties	:	The substance c	r mixture is not classified as oxidizing.
Mol	ecular weight	:	No data available	e
Par	ticle size	:	No data availabl	e

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:

Gonadotropin, pregnant mare serum:

Acute oral toxicity	:	LD50 (Mouse): 120 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Mouse): > 1,700 mg/kg Application Route: Intravenous
		LD50 (Mouse): > 1,700 mg/kg Application Route: Subcutaneous
		LD50 (Rat): 500 mg/kg Application Route: Intravenous



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/09/2016
4.1	10/31/2016	636543-00005	Date of first issue: 05/03/2016

LD50 (Rat): 500 mg/kg Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Ingredients:

Gonadotropin, pregnant mare serum: Remarks: No data available

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:

Gonadotropin, pregnant mare serum:

Remarks: No data available

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:

Gonadotropin, pregnant mare serum:

Remarks: No data available

Germ cell mutagenicity

Not classified based on available information.

:

Ingredients:

Gonadotropin, pregnant mare serum:

Genotoxicity in vivo

Test Type: Cytogenetic assay Species: Mouse Application Route: Intraperitoneal injection Result: positive Remarks: Not classified due to data which are conclusive although insufficient for classification.

Carcinogenicity

Not classified based on available information.

Ingredients:

Gonadotropin, pregnant mare serum:

8 / 14



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

ersion 1	Revision Date: 10/31/2016	SDS Number: 636543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016					
Carci ment	nogenicity - Assess-	: No data availat	ble					
IARC		No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.						
OSH	A	equal to 0.1% is id	No ingredient of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.					
NTP			nis product present at levels greater than or dentified as a known or anticipated carcinoger					
-	oductive toxicity damage fertility. Suspec	ed of damaging the	unborn child.					
Ingre	edients:							
Gona	adotropin, pregnant ma	re serum:						
Епес	ts on fertility	Fertility: LOAEI Result: Effects Remarks: May	ute: Subcutaneous L: 10 μg/kg					
Effec	ts on fetal development		cause birth defects. from similar materials					
Repro sessr	oductive toxicity - As- nent	animal experim	e of adverse effects on development, based on nents., Clear evidence of adverse effects on and fertility, based on animal experiments.					
Gona	adotropin, chorionic:							
Effec	ts on fertility		ute: Intravenous injection L: 8.89 mg/kg body weight					
			ute: Intraperitoneal injection L: 0.883 mg/kg body weight					
		Test Type: Fert Species: Monk Fertility: LOAEI Result: Effects	ey ́ L: 0.224 mg/kg body weight					



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Vers 4.1	ion	Revision Date: 10/31/2016		9S Number: 6543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016
	Effects	on fetal development	:	Species: Hamster Application Route	: Intraperitoneal injection ;ity.: LOAEL: 60 mg/kg body weight
	Reprod sessme	uctive toxicity - As- ent	:	fertility from huma	of adverse effects on sexual function and in epidemiological studies., Some evidence on development, based on animal

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (ovaries) through prolonged or repeated exposure if swallowed.

Ingredients:

Gonadotropin, chorionic:

Target Organs: ovaries Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Ingredients:

Gonadotropin, pregnant mare serum:

Species: Rat NOAEL: 1.5 mg/kg Application Route: Oral Exposure time: 3 Days Symptoms: No adverse effects.

Species: Rat LOAEL: 10 mg/kg Application Route: Oral Exposure time: 14 Days Target Organs: Reproductive organs

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Ingredients:

Gonadotropin, pregnant mare serum:

Inhalation	:	Symptoms: Headache, Fatigue, mood swings, altered mental status, Edema, Allergic reactions, Effects on fertility.
Skin contact	:	Remarks: May produce an allergic reaction.

10 / 14



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 4.1	Revision Date: 10/31/2016	SDS Number: 636543-00005	Date of last issue: 08/09/2016 Date of first issue: 05/03/2016			
Inge	stion	: Remarks: May	be harmful if swallowed.			
	adotropin, chorionic: ation	: Target Organs: ovaries Symptoms: effects on menstruation, gynecomastia, Head- ache, mental depression, Irritability, restlessness, Fatigue				
SECTION	SECTION 12. ECOLOGICAL INFORMATION					
	oxicity ata available					
	istence and degradab i ata available	ility				
	ccumulative potential ata available					
	ility in soil ata available					
	er adverse effects					

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of las
4.1	10/31/2016	636543-00005	Date of firs

Date of last issue: 08/09/2016 Date of first issue: 05/03/2016

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

Ingredients	CAS-No.	Component RQ	Calculated product RQ
		(lbs)	(lbs)
Sodium phosphate, dihydrate	10028-24-7	5000	*

*: Calculated RQ exceeds reasonably attainable upper limit.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	: Chronic Health Hazard
----------------------	-------------------------

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know	V		
Water		77	'32-18-5
Sodium phosphate, dihydrate		nydrate 10	028-24-7
California Prop. 65		This product does not contain any chemica State of California to cause cancer, birth, o reproductive defects.	
The ingredients of this produ	uct	are reported in the following inventories	
AICS	:	not determined	
DSL	:	not determined	


IECSC :	not determined
---------	----------------



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/09/2016
4.1	10/31/2016	636543-00005	Date of first issue: 05/03/2016

SECTION 16. OTHER INFORMATION



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR -No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ -Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Sub-



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date: 10/31/2016	SDS Number:	Date of last issue: 08/09/2016		
4.1		636543-00005	Date of first issue: 05/03/2016		
stance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative					

Revision Date : 10/31/2016

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8